Logo Sangui

Downloads as PDF-File
161122 financials_EN.pdf
161101 sales_agreements_EN.pdf
161014 news_EN.pdf
160929 news_EN.pdf
160606 news_EN.pdf
160201 preliminary figures_EN.pdf
151028 Preliminary 16Q1_EN.pdf
150929 Financials FY15_EN.pdf
150827 Financials FY15_EN.pdf
150626 Preliminary Prospectus.pdf
150602 EWMA_EN.pdf
150515 Financials 15Q3_EN.pdf
150512 Financing_EN.pdf
150318 Preclinical Results EN.pdf
150212 Financials 15Q2_EN.pdf
150203 Eastern Europe_EN.pdf
150128 ShareholderLetter_EN.pdf
150128 Preliminary Q2 Revenues_EN.pdf
141113 Financials 15Q1_EN.pdf
141111 Preclinical Results EN.pdf
141106 OTCQB EN.pdf
141103 Silanes EN.pdf
141007 Q1 Revenues_EN.pdf
140925 Financials FY14_EN.pdf
140806 ARDS_trials_EN2.pdf
140731 Wound Treatment Patent_EN.pdf
140729 Preliminary Q4 Revenues_EN.pdf
140526 woundspray_EN.pdf
140515 Financials 14Q3_EN.pdf
140425 start in vitro tests_EN.pdf
140214 Financials 14Q2_EN.pdf
140114 Shareholder Letter_en.pdf
131205 Three Partners_EN.pdf
131115 infirst_EN.pdf
131106 Financials 14Q1_EN.pdf
131015 ECCPS_EN.pdf
131008 Scherrer_EN.pdf
130927 Financials FY13_EN.pdf
130923 Colpharma EN.pdf
130917 FEA Award_EN.pdf
130910 Ramma_EN.pdf
130904 Hb Patent EN.pdf
130813 Wound Treatment Patent_EN.pdf
130716 MEDiLAB_EN.pdf
130521 PM 9M figures_E.pdf
130422 BiologiQ en.pdf
130409 Additiv_E.pdf
130322 Notiz Berlin_E.pdf
130215 Half year figures_E.pdf
130205 Prague study_published_E.pdf
121221 Mexiko Sales_E.pdf
121212 Prague study_E.pdf
121017 Pegylation patent granted E.pdf
120827 PM Complementing Agreement E.pdf
120813 PM 100 days E.pdf

Media Releases

Sangui BioTech:
  • Granulox® - Follow up

Hamburg, May, 11 2021:
With this letter we would like to briefly summarize the events since the acquisition of Sastomed GmbH by the Mölnlycke Health Care Group and point out the latest developments in the Granulox® wound spray.

The acquisition of SastoMed GmbH by the Mölnlycke Health Care Group at the end of June 2018 was the starting point for an extensive integration and reorganization program with the target of increasing the market potential of the Granulox® wound spray. In addition to adapting the logistical processes, these measures also included legal changes. With the merger of Sastomed GmbH in 2020 with its parent company Mölnylcke Health Care GmbH, Mölnylcke Health Care GmbH is now the contractional licensee of Granulox®. In addition, extensive and sometimes lengthy restructuring process was carried out in the sales area. The integration of Granulox® sales into the sales structure of the Mölnlycke Health Care Group required the reorganization of the partnerships SastoMed GmbH previously entered into in the individual sales territories until 2018. Accordingly, there were temporary slowdown in sales growth in these territories.

At the same time, Granulox® was optically integrated into the portfolio for chronic wound solutions of the Mölnlycke Health Care Group by adapting its brand to the Mölnlycke brand identity (https://www.molnlycke.com/products-solutions/granulox/). These measures will accelerate cross-selling effects and help to further expand the customer base. Another step towards the integration and positioning of Granulox® within the Mölnlycke Health Care Group with corresponding effects on future sales of Granulox® is the integration into a marketing platform (https://www.molnlycke.com/our-knowledge/topical-oxygen- therapy-with-granulox /) as part of the digital strategy of the Mölnlycke Health Care Group, which explains the crucial role of oxygen in the healing of chronic wounds.

Although some measures were impacted by the restrictions associated with the Covid19 pandemic, the integration has been successfully completed.

At the end of 2019, Mölnlycke Health Care Group initiated a European multicenter study to evaluate Granulox® in the therapy of chronic venous leg ulcers (https://clinicaltrials.gov/ct2/show/record/NCT04181320?view=record).Despite the Covid19 pandemic, the study is expected to complete as planned. The expected results of this study, which is unique in the wound healing area due to its scope, will provide further excellent clinical data for the use of Granulox®. This is particularly true in territories such as Germany or France, in which the proof of the effectiveness of the medical device through clinical data will in future be one of the prerequisites for reimbursement by the statutory payers. The results of the study will help establish the treatment of chronic wounds with oxygen as the standard in chronic wound care.

In addition to these encouraging prospects, Mölnlycke Health Care has succeeded in obtaining approval for Granulox® for other territories, including Egypt. Out of 100 million people in Egypt, roughly 15% of the adult population suffer from diabetes, a major cause of diabetic leg ulcers. With the recent market approval of Granulox®, the Egyptian healthcare system has access to a new solution to improve quality and delivery of chronic wound care.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.